Amorphous Solid Dispersions for BCS Class II Antihyperlipidemic Drugs: From Drug-Polymer Interactions to in vivo Performance.

Ridwan S, Pratiwi R, Hildayani SZ, Budiman A

Open source

DOI
10.2147/dddt.s634131
Published
2026
Container
Drug design, development and therapy
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.2147/dddt.s634131,
  title = {Amorphous Solid Dispersions for BCS Class II Antihyperlipidemic Drugs: From Drug-Polymer Interactions to in vivo Performance.},
  author = {Ridwan S and Pratiwi R and Hildayani SZ and Budiman A},
  year = {2026},
  journal = {Drug design, development and therapy},
  doi = {10.2147/dddt.s634131},
  url = {https://doi.org/10.2147/dddt.s634131}
}

RIS

TY  - JOUR
TI  - Amorphous Solid Dispersions for BCS Class II Antihyperlipidemic Drugs: From Drug-Polymer Interactions to in vivo Performance.
AU  - Ridwan S
AU  - Pratiwi R
AU  - Hildayani SZ
AU  - Budiman A
PY  - 2026
JO  - Drug design, development and therapy
DO  - 10.2147/dddt.s634131
UR  - https://doi.org/10.2147/dddt.s634131
ER  - 

APA

S, R., R, P., SZ, H., & A, B. (2026). Amorphous Solid Dispersions for BCS Class II Antihyperlipidemic Drugs: From Drug-Polymer Interactions to in vivo Performance.. Drug design, development and therapy. https://doi.org/10.2147/dddt.s634131

Source records